Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This in-depth analysis shows that the Global Asthma and COPD Drugs Market, valued at ...

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

Roflumilast is used to reduce COPD exacerbations in patients with severe chronic bronchitis. The US market for the drug was valued at approximately $32 million as of June 2024, according to IQVIA ...

The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

Please provide your email address to receive an email when new articles are posted on . Significantly more patients from the injurious fall group had all but one of the studied prescription ...